CompletedPhase 4NCT01298180

Is There a Sensibility Increased in the Growth Hormone at Child With Prader-Willi Syndrome?

Studying Prader-Willi syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University Hospital, Toulouse
Principal Investigator
Maithé TAUBER, MD
University Hospital, Toulouse
Intervention
Growth hormone (Genotonorm® or Omnitrope®)(drug)
Enrollment
111 enrolled
Eligibility
1-5 years · All sexes
Timeline
20092013

Study locations (26)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01298180 on ClinicalTrials.gov

Other trials for Prader-Willi syndrome

Additional recruiting or active studies for the same condition.

See all trials for Prader-Willi syndrome

← Back to all trials